

je to především expozice cytostatikům či radiaci a dlouhodobá imunosuprese. Jejich popis, diagnostika a léčba přesahuje tuto kapitolu. Dovolujeme si jen zmínit sekundární nádory, degenerativní změny různého charakteru, porucha fertility a zvláštnosti u pediatrických pacientů (poruchy růstu a puberty).

Závěr

Alogenní transplantace krvetvorby, i přes stálou snahu rozvinout zcela cílenou léčbu u jednotlivých druhů onemocnění, zůstává důležitou a často jedinou kurativní metodou. Nese s sebou požadavky na extrémně přesnou laboratorní vyšetřovací techniku v předtransplantačním

i peritransplantačním období, stejně tak jako na klinickou péči a požadavky na farmakologickou léčbu i přes různá úskalí, včetně lékové interakce a vyžaduje intenzivní spolupráci všech zúčastněných odvětví. Zároveň se zdá, že některé principy budou společné i pro nově se rozvíjející metody cílené specifické buněčné léčby (16).

LITERATURA

1. Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, Patriarca F, Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scimè R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. *Lancet Oncol*. 2015 Nov; 16(15): 1525–1536.
2. Martino R, de Wreede L, Fiocco M, van Biezen A, von dem Borne PA, Hamladji RM, Volin L, Bornhäuser M, Robin M, Rocha V, de Witte T, Kröger N, Mohty M; Acute Leukemia Working Party the subcommittee for Myelodysplastic Syndromes of the Chronic Malignancies Working Party of the European group for Blood Marrow Transplantation Group (EBMT). Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. *Bone Marrow Transplant*. 2013 Jun; 48(6): 761–770.
3. Shimoni A, Nagler A. Optimizing the conditioning regimen for allogeneic stem-cell transplantation in acute myeloid leukemia; dose intensity is still in need. *Best Pract Res Clin Haematol*. 2011 Sep; 24(3): 369–379.
4. Slavin SI, Aker M, Shapira MY, Resnick I, Bitan M, Or R. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders. *Clin Transpl*. 2003; 275–282.
5. Khafan-Dabaja M1, Mhaskar R, Reljic T, Pidala J, Perkins

- JB, Djulbegovic B, Kumar A. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. *Cochrane Database Syst Rev*. 2014 Jul 25; (7).
6. Theurich S1, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt-Baildon M. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. *Cochrane Database Syst Rev*. 2012 Sep 12; (9).
7. Mielcarek M, Furlong T, O'Donnell PV, Storer BE, McCune JS, Storb R, Carpenter PA, Flowers ME, Appelbaum FR, Martin PJ. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. *Blood*. 2016 Mar 17; 127(11): 1502–1508. doi: 10.1182/blood-2015-10-672071.
8. Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völz A, Ayuk F, Ruutu T, Bonifazi F. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. *N Engl J Med*. 2016 Jan 7; 374(1): 43–53.
9. Baumgartner A, Bargetzi A, Zueger N, Bargetzi M, Medinger M, Bounoure L, Gomes F, Stanga Z, Mueller B, Schuetz P. Revisiting nutritional support for allogeneic hematologic stem cell transplantation—a systematic review. *Bone Marrow Transplant*. 2017 Apr; 52(4).
10. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI,

- Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. *Clin Infect Dis*. 2011 Feb 15; 52(4): e56–93. o
11. Rudoni J, Jan A, Hosing C, Aung F, Yeh J. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients. *Eur J Haematol*. 2018 Sep; 101(3): 389–398.
12. Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, Goebel J, Dixon BP. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. *Blood Rev*. 2015 May; 29(3): 191–204.
13. Richardson P, Aggarwal S, Topaloglu O, Villa KF, Corbacioglu S. Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). *Bone Marrow Transplant*. 2019 Feb 25. doi: 10.1038/s41409-019-0474-8. [Epub ahead of print] Erratum in: *Bone Marrow Transplant*. 2019 Apr 1.
14. Nassereddine S, Rafei H, Elbahesh E, Tabbara I. Acute Graft Versus Host Disease: A Comprehensive Review. *Anticancer Res*. 2017 Apr; 37(4): 1547–1555.
15. Sarantopoulos S, Cardones AR, Sullivan KM. How I treat refractory chronic graft-versus-host disease. *Blood*. 2019 Mar 14; 133(11): 1191–1200. doi: 10.1182/blood-2018-04-785899.
16. Glotzbecker B, Duncan C, Alyea E 3rd, Campbell B, Soiffer R. Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. *Biol Blood Marrow Transplant*. 2012 Jul; 18(7): 989–1006.